Clarke PA - Search Results

1

HSF1 Pathway Inhibitor Clinical Candidate (CCT361814/NXP800) Developed from a Phenotypic Screen as a Potential Treatment for Refractory Ovarian Cancer and Other Malignancies.

Pasqua AE, Sharp SY, Chessum NEA, Hayes A, Pellegrino L, Tucker MJ, Miah A, Wilding B, Evans LE, Rye CS, Mok NY, Liu M, Henley AT, Gowan S, De Billy E, Te Poele R, Powers M, Eccles SA, Clarke PA, Raynaud FI, Workman P, Jones K, Cheeseman MD. Pasqua AE, et al. Among authors: clarke pa. J Med Chem. 2023 Apr 27;66(8):5907-5936. doi: 10.1021/acs.jmedchem.3c00156. Epub 2023 Apr 5. J Med Chem. 2023. PMID: 37017629 Free PMC article.

2

Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma.

Waters JS, Webb A, Cunningham D, Clarke PA, Raynaud F, di Stefano F, Cotter FE. Waters JS, et al. Among authors: clarke pa. J Clin Oncol. 2000 May;18(9):1812-23. doi: 10.1200/JCO.2000.18.9.1812. J Clin Oncol. 2000. PMID: 10784621 Clinical Trial.

3

Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis.

Hostein I, Robertson D, DiStefano F, Workman P, Clarke PA. Hostein I, et al. Among authors: clarke pa. Cancer Res. 2001 May 15;61(10):4003-9. Cancer Res. 2001. PMID: 11358818

4

Innovative cancer drug targets: genomics, transcriptomics and clinomics.

Workman P, Clarke PA. Workman P, et al. Among authors: clarke pa. Expert Opin Pharmacother. 2001 Jun;2(6):911-5. doi: 10.1517/14656566.2.6.911. Expert Opin Pharmacother. 2001. PMID: 11585007 No abstract available.

5

Gene expression microarray analysis in cancer biology, pharmacology, and drug development: progress and potential.

Clarke PA, te Poele R, Wooster R, Workman P. Clarke PA, et al. Biochem Pharmacol. 2001 Nov 15;62(10):1311-36. doi: 10.1016/s0006-2952(01)00785-7. Biochem Pharmacol. 2001. PMID: 11709192 Review.

6

Inhibition of Kirsten-ras expression in human colorectal cancer using rationally selected Kirsten-ras antisense oligonucleotides.

Ross PJ, George M, Cunningham D, DiStefano F, Andreyev HJ, Workman P, Clarke PA. Ross PJ, et al. Among authors: clarke pa. Mol Cancer Ther. 2001 Nov;1(1):29-41. Mol Cancer Ther. 2001. PMID: 12467236

7

Genes and proteins governing the cellular sensitivity to HSP90 inhibitors: a mechanistic perspective.

Maloney A, Clarke PA, Workman P. Maloney A, et al. Among authors: clarke pa. Curr Cancer Drug Targets. 2003 Oct;3(5):331-41. doi: 10.2174/1568009033481822. Curr Cancer Drug Targets. 2003. PMID: 14529385 Review.

8

Characterisation of molecular events following cisplatin treatment of two curable ovarian cancer models: contrasting role for p53 induction and apoptosis in vivo.

Clarke PA, Pestell KE, Di Stefano F, Workman P, Walton MI. Clarke PA, et al. Br J Cancer. 2004 Oct 18;91(8):1614-23. doi: 10.1038/sj.bjc.6602167. Br J Cancer. 2004. PMID: 15452549 Free PMC article.

9

Gene expression microarray technologies in the development of new therapeutic agents.

Clarke PA, te Poele R, Workman P. Clarke PA, et al. Eur J Cancer. 2004 Nov;40(17):2560-91. doi: 10.1016/j.ejca.2004.07.024. Eur J Cancer. 2004. PMID: 15541959 Review.

10

Solid-phase immunoassays in mechanism-based drug discovery: their application in the development of inhibitors of the molecular chaperone heat-shock protein 90.

Hardcastle A, Boxall K, Richards J, Tomlin P, Sharp S, Clarke P, Workman P, Aherne W. Hardcastle A, et al. Assay Drug Dev Technol. 2005 Jun;3(3):273-85. doi: 10.1089/adt.2005.3.273. Assay Drug Dev Technol. 2005. PMID: 15971989

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

209 results

Search Page

Filters